MannKind Corporation (NASDAQ:MNKD) faces an FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on April 1, 2014, for the review of the company’s New Drug Application (NDA) for Afrezza, an ultra rapid-acting insulin developed for the treatment of adult patients with type 1 or type 2 diabetes. Obviously, if the committee will recommend the drug for approval, it could impact the stock price in a significant manner. However, there was a lot of skepticism around the company and the stock in the past few years. MannKind has twice received Complete Response letters (CRLs) from the FDA when seeking approval for Afrezza. MannKind Corporation (NASDAQ:MNKD) shares after opening at $5.66 moved to $6.20 on last trade day and at the end of the day closed at $5.69. Company price to cash ratio in past twelve months was calculated 27.11.
Inovio Pharmaceuticals (NYSE:INO) had its price target upped by Maxim Group from $3.00 to $6.00 in a research note issued to investors on Tuesday, Analyst Ratings.Net reports. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares advanced 11.37% in last trading session and ended the day on $3.82. INO return on equity ratio is recorded as -124.40% and its return on assets is -84.90%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) yearly performance is 620.75%.
The Shareholders Foundation announces that an investor, who purchased shares of Geron Corporation (NASDAQ:GERN), filed a lawsuit in the United States District Court for the Northern District of California over alleged violations of Federal Securities Laws by Geron in connection with certain allegedly false and misleading statements made between June 16, 2013 and March 11, 2014. Geron Corporation (NASDAQ:GERN) shares moved down -8.06% in last trading session and was closed at $2.28, while trading in range of $2.21 – 2.46 .Geron Corporation (NASDAQ:GERN) year to date (YTD) performance is -51.90%.
Even after a resurrected sales approval from the Federal Drug Administration Authority in the US Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s shares are still facing the brunt of the October recall of Iclugis. Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) weekly performance is 5.41%. On last trading day company shares ended up $8.19. Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is 5.04%. Analysts mean target price for the company is $8.56.
Leave a Reply